Zepuping (gecacitinib) - Suzhou Zelgen
Inrebic (fedratinib) - BMS
navtemadlin (KRT-232) - Kartos Therapeutics, Ipsen
Jakafi (ruxolitinib) - Incyte
navitoclax (ABT 263) - AbbVie
bezacitinib (OB756) - Biosun Pharma
Vonjo (pacritinib) - SOBI
pelabresib (DAK539) - Novartis
Ojjaara (momelotinib) - GSK
https://www.sciencedirect.com/science/article/abs/pii/S2152265026023876
 
Muhammad Ashar Ali MD 1; Wajeeha Aiman MD 2; Anna Koget DO 1; Arjun Lakshman MD 1; Salman Fazal MD 3
 
Sep 1, 2026
 
Prev Next